Eversept Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Eversept Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40.2M	Buy	+90,000	New	+$42M	2.12%	13
2022 Q1	–	Sell	-94,100	Closed	-$20.7M	–	107
2021 Q4	$20.7M	Sell	94,100 -79,200	-46%	-$15.4M	1.32%	21
2021 Q3	$31.4M	Hold	173,300	–	–	2.17%	18
2021 Q2	$34.9M	Buy	173,300 +113,300	+189%	+$23.7M	2.33%	14
2021 Q1	$12.9M	Buy	+60,000	New	+$13.2M	0.97%	30

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Eversept Partners's VRTX Position: Q3 2021 in Review

Eversept Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 54,500 shares — an estimated $10.6M sold.

Eversept Partners first reported a position in VRTX in Q4 2017 and held it in 10 quarters. The position peaked at $16M in Q4 2019. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Eversept Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Eversept Partners sold 54,500 Vertex Pharmaceuticals shares in Q3 2021, an estimated $10.6M.
Eversept Partners first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 10 quarters.
Eversept Partners's Vertex Pharmaceuticals position peaked at $16M in Q4 2019.
933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.